July 2026
1. 
   Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.
   Lancet. 2026 Jul 1:S0140-6736(26)00758-0. doi: 10.1016/S0140-6736(26)00758.
   

   >> Share

   
   May 2026
2. POULTER NR, Beaney T, Kerr GK, Kiru G, et al
   The role of community-based blood pressure screening in improving hypertension care.
   Lancet. 2026 May 6:S0140-6736(26)00379-X. doi: 10.1016/S0140-6736(26)00379.
   

   >> Share

   
   April 2026
3. ZENG G, Bidel Z, Yang Q, Canoy D, et al
   Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
   Lancet. 2026;407:1626-1638.
   

   >> Share

   
   March 2026
4. KASUJJA FX, Aikaeli F, Garrib A, van Widenfelt E, et al
   Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.
   Lancet. 2026;407:1084-1094.
   

   >> Share

   
   
5. AZIZI M, Brown JM, Dwyer JP, Flack JM, et al
   Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
   Lancet. 2026;407:988-999.
   

   >> Share

   
   
6. MAHFOUD F, Lauder L
   Aldosterone synthase inhibition in resistant hypertension: promises and unknowns.
   Lancet. 2026;407:922-923.
   

   >> Share

   
   February 2026
7. AZIZI M, Tuttle KR, Brown JM, Piskorz DL, et al
   New drug therapies for hypertension.
   Lancet. 2026 Feb 10:S0140-6736(25)02064-1. doi: 10.1016/S0140-6736(25)02064.
   

   >> Share

   
   November 2025
8. FARRAR J, Frieden T
   WHO global report on hypertension 2025.
   Lancet. 2025;406:2318-2319.
   

   >> Share

   
   August 2025
9. WANG N, Salam A, Pant R, Kumar A, et al
   Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.
   Lancet. 2025;406:915-925.
   

   >> Share

   
   
10. MCEVOY JW
    Optional hypertension: a new concept emerging from trials of intensive blood pressure control.
    Lancet. 2025 Aug 28:S0140-6736(25)01670-8. doi: 10.1016/S0140-6736(25)01670.
    

    >> Share

    
    
11. GUO X, Sun G, Xu Y, Zhou S, et al
    Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
    Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
    

    >> Share

    
    May 2025
12. FRIEDEN TR, Garg R, Moran AE, Whelton PK, et al
    Improved hypertension care requires measurement and management in health facilities, not mass screening.
    Lancet. 2025 May 7:S0140-6736(25)00561-6. doi: 10.1016/S0140-6736(25)00561.
    

    >> Share

    
    January 2025
13. MCCARTHY CP, Bruno RM, Rahimi K, Touyz RM, et al
    Global and European landscape of major hypertension guidelines.
    Lancet. 2025 Jan 15:S0140-6736(24)02795-8. doi: 10.1016/S0140-6736(24)02795.
    

    >> Share

    
    October 2024
14. RODGERS A, Salam A, Schutte AE, Cushman WC, et al
    Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical tria
    Lancet. 2024;404:1536-1546.
    

    >> Share

    
    
15. ANTONOPOULOU M, Chliveros K
    A novel low-dose triple single-pill combination for hypertension.
    Lancet. 2024;404:1496-1498.
    

    >> Share

    
    August 2024
16. 
    General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
    Lancet. 2024;404:851-863.
    

    >> Share

    
    July 2024
17. WERNHART M, Wiesinger C, Windpessl M, Madl-Liebenberger L, et al
    A visual diagnosis of phaeochromocytoma crisis characterised by cyclic fluctuations of blood pressure: be on the look-out for rapid changes.
    Lancet. 2024;404:375-376.
    

    >> Share

    
    
18. RAHIMI K
    Mounting evidence in favour of the lower, the better blood pressure paradigm.
    Lancet. 2024;404:216-217.
    

    >> Share

    
    June 2024
19. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    

    >> Share

    
    
20. HAYASHI SI, Kawano Y, Morishita R, Kusano KF, et al
    Time-lagged amelioration of vascular endothelial function in malignant hypertension: different organs improved at different rates.
    Lancet. 2024;403:2630-2631.
    

    >> Share

    
    May 2024
21. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    

    >> Share

    
    
22. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    

    >> Share

    
    
23. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    

    >> Share

    
    March 2024
24. BAUDIN E, Goichot B, Berruti A, Hadoux J, et al
    Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet. 2024;403:1061-1070.
    

    >> Share

    
    
25. DE LA SIERRA A, Staplin N, Ruilope LM, Baigent C, et al
    Ambulatory blood pressure monitoring and mortality - Authors' reply.
    Lancet. 2024;403:812.
    

    >> Share

    
    
26. LIU W, Ge W, Fan X, Du Y, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:811-812.
    

    >> Share

    
    
27. MARTINEZ-GARCIA MA, Pengo MF, Parati G
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810-811.
    

    >> Share

    
    
28. CHU WM, Ho HE, Wei JC
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810.
    

    >> Share

    
    
29. LI SQ, Zhou JP, Wang Y, Li QY, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:809-810.
    

    >> Share

    
    November 2023
30. JACKSON R, Rodgers A
    The ESH guidelines and missed prevention opportunities.
    Lancet. 2023;402:1729-1730.
    

    >> Share

    
    October 2023
31. MESSERLI FH, Bangalore S, Mandrola JM
    beta blockers switched to first-line therapy in hypertension.
    Lancet. 2023 Oct 13:S0140-6736(23)01733-6. doi: 10.1016/S0140-6736(23)01733.
    

    >> Share

    
    
32. KIVUYO S, Birungi J, Okebe J, Wang D, et al
    Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
    Lancet. 2023;402:1241-1250.
    

    >> Share

    
    
33. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share